Document:

lmnl-ex419_17.htm

Exhibit 4.19

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE LIMINAL BIOSCIENCES INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO LIMINAL BIOSCIENCES INC. IF PUBLICLY DISCLOSED.

 

ProMetic BioSciences Inc. 

500, boul. Cartier Ouest

Bureau 150

Laval (Québec)

H7V 5B7

 

and 

ProMetic Life Sciences Inc.

531, boulevard des Prairies,

Édifice 15,

Laval (Québec)

H7V 1B7

 

RE: ENTENTE PBI-1101, PBI-1402

CESSION DE DROITS INTERVENUE EN LA VILLE DE MONTREAL, PROVINCE DE QUÉBEC, 

LE 17 OCTOBRE 2001 (the « Assignment Agreement »)

 

 

We, Innovon Pharmaceutiques Inc. (‘’Innovon’’) and Pierre Laurin, refer to the Assignment Agreement and hereby confirm that, as of this date: 

 

	
 
	
-
	
ProMetic BioSciences Inc. (‘’PBI’’) has fully complied with all of its obligations under the Assignment Agreement, including, without limitation, the obligation of section 5 to keep Innovon and Pierre Laurin regularly informed of its activities in relation to the development and commercialization of PBI-1101 and PBI-1402; and

 

	
 
	
-
	
Neither Pierre Laurin nor Innovon has sent a notice to PBI [***].

 

Furthermore, we also confirm that: 

 

	
 
	
-
	
In the Assignment Agreement, reference to PBI-1402 and analogues means and includes [***] covered in the issues and pending patent applications listed in Schedule A hereto;

 

	
 
	
-
	
The Assignment Agreement does not relate to the following family of compounds: [***];

 

	
 
	
-
	
The Assignment Agreement excludes [***]; and

 

 

	
 
	
-
	
Innovon and Pierre Laurin were duly notified by PBI, of PBI’s decision [***] in relation to [***] and agreed that PBI should [***] on the understanding that PBI would [***] upon Innovon’s written request.

 

SIGNED THIS _____23____________ OF _______May_____________ 2012

 

 

INNOVON PHARMACEUTIQUE INC. 

 

__/s/ Pierre Laurin___________________________/s/ Pierre Laurin_______________________

By:Pierre LaurinPIERRE LAURIN

Title:President

 

 

ACKNOWLEDGED AND AGREED TO BY: 

 

 

PROMETIC BIOSCIENCES INC. 

 

 

___/s/ Patrick Sartore_______________

By: Patrick Sartore

Title: Senior Legal Counsel and Corporate

 

 

 

PROMETIC LIFE SCIENCES INC. 

 

 

___/s/ Kim Anthony________________

By: Kym Anthony, Chairman of the Boardlmnl-ex420_16.htm

Exhibit 4.20 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE LIMINAL BIOSCIENCES INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO LIMINAL BIOSCIENCES INC. IF PUBLICLY DISCLOSED.

 

AMENDMENT TO ENTENTE PBI – 1101, PBI 1402

Amending Agreement dated December 14, 2015 between ProMetic Biosciences Inc. ("PBI"), ProMetic Life Sciences ("PLI"), Innovon Pharmaceutiques Inc. ("Innovon") and Mr. Pierre Laurin ("PL").

WHEREAS:

	
 
	
(a)
	
PBI, PLI, Innovon and PL (collectively, "the Parties") are parties to an Entente PBI-1101, PBI-1402 dated October 17, 2001 (the "Contract"), a copy of which is attached hereto as Exhibit A; and

	
 
	
(b)
	
The Parties wish to amend the Contract as set out herein.

In consideration of the above and for other good and valuable consideration, the parties agree as follows:

	
Section 1
	
Defined Terms.

All capitalized terms used in this Amending Agreement that are not defined in this Amending Agreement have the meanings ascribed to such terms in the Contract.

	
Section 2
	
Amendment.

The Contract is hereby amended, with effect as of January 1, 2012, to (a) suspend, until [***], any and all rights of retrocession applicable to any or all of PBI-1101 and PBI-1402 and any and all related intellectual property and benefiting PL and Innovon (i.e. contained in sections 3-6 of the Contract) and (b) provide that such retrocession rights will only be effective upon each of Innovon and PL delivering written notice to PBI accepting such retrocession.

	
Section 3
	
Binding Nature.

This agreement becomes effective when executed by all of the parties.  After that time, it will be binding upon and enure to the benefit of the parties and their respective successors, legal representatives and permitted assigns.  Neither this agreement nor any of the rights or obligations under this agreement, including any right to payment, may be assigned or transferred, in whole or in part, by any party without the prior written consent of the other parties.

 

- 2 -

 

	
Section 4
	
Governing Law.

This agreement is governed by, and will be interpreted and construed in accordance with, the laws of the Province of Québec and the federal laws of Canada applicable therein.

The parties agree that the courts of the District of Montréal, Province of Quebec, Canada, will have exclusive jurisdiction for the adjudication of any and all disputes or controversies arising out of or relating directly or indirectly to this agreement and waive any objections to the assertion or exercise of jurisdiction by such courts, including any objection based on forum non conveniens.

	
Section 5
	
Counterparts.

This agreement may be executed in any number of counterparts, each of which is deemed to be an original, and such counterparts together constitute one and the same instrument. Transmission of an executed signature page by facsimile, email or other electronic means is as effective as a manually executed counterpart of this agreement.

	
Section 6
	
English Language.

The parties have agreed that this agreement as well as any notice, document or instrument relating to it be drawn up in English only. Les parties aux présentes ont convenu que la présente convention ainsi que tous autres avis, actes ou documents s'y rattachant soient rédigés en anglais seulement.

[Remainder of page intentionally left blank.  Signature page(s) follow]

 

 

 

The parties have executed this agreement.

				
	
 
	
 
	
PROMETIC BIOSCIENCES INC.

	
By:
	
/s/ Patrick Sartore

	
 
	
Authorized Signing Officer

 

				
	
 
	
 
	
prometic life sciences

	
By:
	
/s/ Patrick Sartore

	
 
	
Authorized Signing Officer

 

				
	
 
	
 
	
INNOVON PHARMACEUTIQUES INC.

	
By:
	
/s/ Pierre Laurin

	
 
	
Authorized Signing Officer

	
 
	
 
	
 

	
/s/ Pierre Laurin

	
Pierre Laurin

 

Signature Page for Consent and Acknowledgment

 

Exhibit A

Entente PBI-1101, PBI-1402lmnl-ex421_15.htm

 

Exhibit 4.21

CONSENT AND ACKnowledgement

Consent and acknowledgement dated December 14, 2015 between ProMetic Biosciences Inc. ("PBI"), Innovon Pharmaceutiques Inc. ("Innovon"), Mr. Pierre Laurin ("PL") and ProMetic Pharma SMT Limited ("PBI LTD").

RECITALS:

	
 
	
(a)
	
PBI, Innovon, PL and ProMetic Life Sciences Inc. are parties to an Entente PBI-1101, PBI-1402 dated October 17, 2001 (the "Contract"), a copy of which is attached hereto as Exhibit A;

	
 
	
(b)
	
PBI wishes to effect an internal reorganization pursuant to which it will be assigning and transferring all of its small molecule therapeutics intellectual property outside of Canada (the "ROW IP") to PBI LTD (the "Reorganization") 

	
 
	
(c)
	
Pursuant to the Contract, PBI requires Innovon's and PL's consent to effect the Reorganization; and

	
 
	
(d)
	
The parties wish to amend the Contract, as more specifically set out herein.

In consideration of the above and for other good and valuable consideration, the parties agree as follows:

	
Section 1
	
Consent.

Innovon and PL hereby irrevocably consent to the Reorganization, including the assignment and transfer of the ROW IP.

	
Section 2
	
Further Assurances.

On or after the date of this agreement, each party shall execute and deliver such documents and take all such action as is reasonably required to carry out the intent and purpose of this agreement.

	
Section 3
	
Binding Nature.

This agreement becomes effective when executed by all of the parties.  After that time, it will be binding upon and enure to the benefit of the parties and their respective successors, legal representatives and permitted assigns.  Neither this agreement nor any of the rights or obligations under this agreement, including any right to payment, may be assigned or transferred, in whole or in part, by any party without the prior written consent of the other parties.

 
 

- 2 -

 

	
Section 4
	
Governing Law.

This agreement is governed by, and will be interpreted and construed in accordance with, the laws of the Province of Québec and the federal laws of Canada applicable therein.

The parties agree that the courts of the District of Montréal, Province of Quebec, Canada, will have exclusive jurisdiction for the adjudication of any and all disputes or controversies arising out of or relating directly or indirectly to this agreement and waive any objections to the assertion or exercise of jurisdiction by such courts, including any objection based on forum non conveniens.

	
Section 5
	
Counterparts.

This agreement may be executed in any number of counterparts, each of which is deemed to be an original, and such counterparts together constitute one and the same instrument. Transmission of an executed signature page by facsimile, email or other electronic means is as effective as a manually executed counterpart of this agreement.

	
Section 6
	
English Language.

The parties have agreed that this agreement as well as any notice, document or instrument relating to it be drawn up in English only. Les parties aux présentes ont convenu que la présente convention ainsi que tous autres avis, actes ou documents s'y rattachant soient rédigés en anglais seulement.

[Remainder of page intentionally left blank.  Signature page(s) follow.]

 

 

 

The parties have executed this agreement.

				
	
 
	
 
	
PROMETIC BIOSCIENCES INC.

	
By:
	
/s/ Patrick Sartore

	
 
	
Authorized Signing Officer

	
 
	
 
	
PROMETIC PHARMA SMT LIMITED

	
By:
	
/s/ Patrick Sartore

	
 
	
Authorized Signing Officer

	
 

	
 
	
 
	
INNOVON PHARMACEUTIQUES INC.

	
By:
	
/s/ Pierre Laurin

	
 
	
Authorized Signing Officer

	
 
	
 
	
 

	
/s/ Pierre Laurin

	
Pierre Laurin

[Signature Page for Consent and Acknowledgment]

- 2 -

 

 

Exhibit A

Entente PBI-1101, PBI-1402

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]